Print Page   |   Contact Us   |   Sign In   |   Join
Business Wire Life Sciences News (US)
Share |

Model N to Host Life Sciences Commercial and Pricing Innovation Forum in Vienna, AustriaOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE:MODN), the leading provider of cloud-based revenue management solutions to life sciences, technology and manufacturing companies, today announced it will host the Commercial and Pricing Innovation Forum on October 10-12, 2017, at the Palais Hansen Kempinski in Vienna, Austria. The Forum is designed to drive innovation among thought leaders from industry experts and pharmaceutical, medical device and technology companies. “The Life Scien

 

Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug DesignationOpen in a New Window

PARIS--(BUSINESS WIRE)--Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation.

 

TherapeuticsMD Announces Pricing of Common Stock OfferingOpen in a New Window

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD Prices Offering

 

GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare ConferenceOpen in a New Window

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on September 27, 2017, at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City. The GTx presentation will begin at 8:35 am EDT. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until October 11, 2017.

 

TherapeuticsMD Announces Public Offering of 12.4 Million Shares of Common StockOpen in a New Window

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD Announces Public Offering

 

Calyxt to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceOpen in a New Window

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Calyxt to Present at the Ladenburg Thalmann 2017 Healthcare Conference

 

Aeterna Zentaris Announces Appointment of Interim Chief Financial OfficerOpen in a New Window

CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer

 

Calyxt Advances Herbicide-Tolerant Wheat and Improved Oil Composition Canola Product Candidates to Phase 1Open in a New Window

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Calyxt Advances Herbicide-Tolerant Wheat and Improved Oil Composition Canola Product Candidates to Phase 1

 

Kadmon Announces Proposed Public Offering of Common Stock and WarrantsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) today announced its intention to offer and sell shares of its common stock and warrants to purchase shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC and Piper Jaffray & Co. are acting as t

 

Catalent, Inc. Announces Public Offering of Common Stock to Fund Part of its Acquisition of Cook PharmicaOpen in a New Window

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has launched an underwritten public offering (the “Offering”) of $250.0 million of its common stock. In connection with the Offering, Catalent intends to grant the underwriters an option for 30 days to purchase up to $37.5 million of additional shares of its com

 

Latest Yes on Issue 2 Ad a Wake-Up Call for OhioansOpen in a New Window

COLUMBUS--(BUSINESS WIRE)--Latest ‘Yes on Issue 2’ Ad a Wake-Up Call for Ohioans - Voting Yes on Issue 2 holds drug companies accountable for price-gouging

 

Zoetis to Participate in the Cantor Fitzgerald Global Healthcare ConferenceOpen in a New Window

PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis will participate in the Cantor Fitzgerald Global Healthcare Conference on Tuesday, Sept. 26, 2017, in New York, N.Y.

 

9 of the Top 15 Medical Device and Diagnostic Companies Move to Veeva VaultOpen in a New Window

SAN JOSE, Calif.--(BUSINESS WIRE)--Today at Advamed’s 2017 MedTech Conference, Veeva Systems (NYSE: VEEV) announced that Veeva Vault is helping a growing number of medical device and diagnostics companies improve quality and efficiency to meet new compliance standards. In less than one year, Veeva has seen nearly 25% growth in medical device and diagnostics customers as organizations prepare to meet rigorous compliance requirements from global health authorities and the international standards

 

BioMarker Strategies Announces United States Patent for PathMAP Functional Signaling Profile TechnologyOpen in a New Window

ROCKVILLE, Md.--(BUSINESS WIRE)--BioMarker Strategies today announced a patent in the United States for its PathMAP Functional Signaling Profile technology for solid tumor cancers.

 

Samsung Device Solutions America Hosts 7th Annual “Gears for Giving” Charity Event to Help Find a Cure for Childhood CancerOpen in a New Window

SAN JOSE, Calif.--(BUSINESS WIRE)--Samsung Device Solutions America hosted the seventh-annual “Gears for Giving” charity event last week, where it was joined by hundreds of participants including Samsung and Cisco employees to raise money for St. Jude Children’s Research Hospital. Gears for Giving is a bike, walk, run and cheer event that originated at Samsung Device Solutions America headquarters in Silicon Valley. This year’s event included the option for a 10-mile bike ride on the Guadalupe

 

Teva Announces Reintroduction of Generic Depo-Provera® in the United StatesOpen in a New Window

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy. “This reintroduction brings an additional product to a market that was previously lacking in options,” said Dr. Haf

 

Health Mart® Kicks-Off New ‘Revenue Remedies’ Town Hall SeriesOpen in a New Window

IRVING, Texas--(BUSINESS WIRE)--Peer-to-Peer Continuing Education Series to Provide Strategies for Growing Revenue While Improving Patient Outcomes

 

MetaStat Announces Upcoming Investor and Pharmaceutical Industry Partnering Conference PresentationsOpen in a New Window

BOSTON--(BUSINESS WIRE)--#breastcancer--MetaStat, Inc. (OTCQB:MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, announced today that its CEO Douglas A. Hamilton will present at the following Investor and Pharmaceutical Industry Partnering Conferences. BioPharm America™ 2017 – 10 International Partnering ConferenceSheraton Hotel, Boston, MATuesday, September 26th, 2017Time: 10:45 a.m. ESTIndependence East, Level 2https://ebdgroup.knect365.com/

 

Independent Study Shows Alcat Test Can Significantly Improve Symptom Severity for Those with Irritable Bowel SyndromeOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Researchers at Yale School of Medicine reported a landmark study in BMJ Open Gastroenterology showing that patients with irritable bowel syndrome (IBS) who follow individualized diets based on a particular food sensitivity blood test experienced significant symptom improvement. The study, led by Ather Ali, assistant professor of pediatrics and medicine at Yale School of Medicine and Wajahat Mehal, M.D., Ph.D., Internal Medicine Dept. (Digestive Diseases), Yale School

 

TransMed7, LLC Announces Breast Health Chair AppointmentOpen in a New Window

PORTOLA VALLEY, Calif.--(BUSINESS WIRE)--TransMed7, LLC, today announced the appointment of Richard E. Fine, MD, as Chair, Breast Health Team and Member, Executive Team of TransMed7’s Clinical and Scientific Advisory Board (CSAB). "We are honored to have Dr. Fine as Chair of the distinguished leaders in our Breast Health Team. He brings to our organization more than 20 years’ experience as a nationally recognized pioneer in breast care,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO. “I

 

“Domino for Good” Catalyzes the Impact of Data Science Beyond the EnterpriseOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Domino Data Lab, the makers of an innovative, collaborative data science platform, today announced the launch of Domino for Good, a social impact initiative that provides nonprofits, academia and students with access to its technology, mentorship and data scientists. The program’s commitment to advancing society through data science collaboration aims to have a wide-reaching, profound impact on global issues such as poverty, disease and public safety. The launch

 

Report: Counterfeit Medications Containing Deadly Fentanyl Have Been Found in 40 StatesOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--A newly-released report on counterfeit medicines is placing the spotlight on a problem that may be far worse than is commonly believed. According to the review conducted by The Partnership for Safe Medicines, counterfeit prescription drugs containing the deadly ingredient fentanyl, most often illegally imported, have been found in as many as 40 states and are tied to deaths in more than a dozen states. The report was compiled by reviewing court records, statements b

 

CURE Media Group Expands Strategic Alliance Partnership Program With The National Pancreas FoundationOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group Expands Strategic Alliance Partnership Program With The National Pancreas Foundation

 

Ireland's Medtech Industry Expansion Fueled by Access to Talent, Digital Devices and Data ExpertiseOpen in a New Window

SAN JOSE, Calif.--(BUSINESS WIRE)--Fourteen of Top 15 Global Medtech Firms Now Have Irish Facilities, Responding to Ireland's "One-Stop Shop" Location

 

OncLive® Presents State of the Science Summit™: Lung CancerOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® Presents State of the Science Summit™: Lung Cancer

 

Douglas A. Ducey, Governor of the State of Arizona, to be Honored as the Arizona Bioscience Leader of the Year at the 2017 AZBio AwardsOpen in a New Window

CHANDLER, Ariz.--(BUSINESS WIRE)--#AZBW--Gov. Douglas A. Ducey honored by AZBio for strategic investments in research infrastructure and education as Arizona Bioscience Leader of the Year.

 

Mazor Robotics to Present at the Ladenburg Thalmann Healthcare ConferenceOpen in a New Window

CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical robotic systems, announced today that management is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 26, 2017 at 10:00am ET. A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website. About Mazor Mazor Robotics (TASE: MZOR; NASDAQ

 

Lane Bryant to Partner with the Breast Cancer Research Foundation (BCRF)Open in a New Window

COLUMBUS, Ohio--(BUSINESS WIRE)--In the fight against breast cancer, plus-size apparel retailer Lane Bryant recognizes that there is strength in numbers. So this October, the brand will continue to support the fight against breast cancer through a new charitable partnership with the Breast Cancer Research Foundation (BCRF). Starting September 25, donations generated by Lane Bryant throughout the month of October will benefit a special research initiative funded through BCRF: a project studying

 

Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic DiseasesOpen in a New Window

BRYN MAWR, Pa.--(BUSINESS WIRE)--Opsidio, LLC raises funding to develop novel therapy for fibrotic and remodeling diseases.

 

SanBio Names Mohammad El-Kalay New Technical Operations SVPOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio, Inc. today announced the appointment of Mohammad El-Kalay, PhD, as Senior Vice President of Technical Operations.

 

Michael Gavin Appointed New CEO of Injured Workers' Pharmacy, LLC.Open in a New Window

ANDOVER, Mass.--(BUSINESS WIRE)--Michael Gavin Appointed New CEO of Injured Workers' Pharmacy, LLC.

 

Evoqua’s ADI Systems Recognized with New Brunswick Bioscience AwardOpen in a New Window

PITTSBURGH & FREDERICTON, NB--(BUSINESS WIRE)--Evoqua's ADI wins Bioscience award

 

Aortica™ Corp. Reports Successful Results of First 30 Fenestrated EVAR Patients Using Automated Case Planning SoftwareOpen in a New Window

BELLEVUE, Wash.--(BUSINESS WIRE)--#AAA--Aortica reports successful results for the first 30 patients undergoing FEVAR using Aortica’s AORTAFIT™ automated case planning software.

 

Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic AreaOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced the appointment of Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective today. In her new role, Ms. Lee will be responsible for the design and execution of commercial strategy for the company’s late-stage Alzheimer’s disease assets and will work in partnership with Biogen’s Research & Development function in overseeing Biogen’s entire Alzheimer’s portfolio. She will be based in Cambridge, Mass., and

 

New Atellica™ Solution, Advanced Diagnostics Analyzers from Siemens Healthineers, Now Available for SaleOpen in a New Window

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Siemens Healthineers announced today the CE Mark and global commercial availability of its Atellica™ Solution—flexible, scalable, automation-ready immunoassay and chemistry analyzers. The solution is now available across the globe in Europe, the United States, South America and Asia3. The Atellica Solution provides laboratory diagnostics professionals control and simplicity so they can spend more time driving outcomes and less time on operations. “The launch of

 

Stratpharma Takes Top Honors Across Multiple Categories in the 2017 Aesthetic Everything Diamond Crystal AwardsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Stratpharma recognized for its leadership across industry, product and management categories.

 

Evaluate Ltd: Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022Open in a New Window

LONDON & BOSTON & TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Evaluate's EvaluateMedTech World Preview 2017, Outlook to 2022 reveals Medtronic was 2016's leading medtech co. with sales of > $30bn.

 

Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar’s Global Commercial Control of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human DrugOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Health subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals signed an agreement returning key rights in India and 140 other countries.

 

ExxonMobil Expands Methane Emissions Reduction ProgramOpen in a New Window

FORT WORTH, Texas--(BUSINESS WIRE)--ExxonMobil Expands Methane Emissions Reduction Program

 

Innovation Health Announces Pilot Program with Sanofi to Improve Care Delivery for People Living with Type 2 DiabetesOpen in a New Window

FALLS CHURCH, Va.--(BUSINESS WIRE)--Innovation Health, a unique partnership between two industry leaders, Inova and Aetna, and Sanofi, a global health care leader, today announced a new pilot program for people living with Type 2 diabetes. The pilot program will work to study the impact of novel digital health solutions from One Drop® and Gocap® to help patient outcomes and medication adherence. “Creating unique relationships and implementing innovative care solutions is part of Innovation Heal

 

Ligand to Host Analyst Day on November 14th in New York CityOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.m. to 5:30 p.m. Eastern time (1:00 p.m. to 2:30 p.m. Pacific time) in New York City. Company presenters will include: John Higgins, Chief Executive Officer Matt Foehr, President and Chief Operating Officer Matt Korenberg, Chief Financial Officer Members of Ligand’s scientific leadership presenting the OmniAb technology and GRA program The event will b

 

MdBio Foundation Marks 16 School Years of Mobile STEM EducationOpen in a New Window

GAITHERSBURG, Md.--(BUSINESS WIRE)--MdBio's new MXLab and $1.36 million grant from Verizon brings hands-on learning to students throughout Maryland and Washington, D.C.

 

Endourology Society Honors CreisselOpen in a New Window

BLOOMINGTON, Ind.--(BUSINESS WIRE)--#cookmedical--Jean-Marc Creissel received the Endourology Society 2017 Industry Award during the society’s annual World Congress of Endourology and SWL in Vancouver. Creissel is vice president of Cook Medical’s Urology business unit and vice president of operations for the greater China region. The award is presented by the society’s awards committee to an individual and the company they represent for their efforts promoting Endourology worldwide. Creissel joins three prev

 

Pilgrim Quality Solutions to Present and Exhibit at 2017 American Medical Device SummitOpen in a New Window

TAMPA, Fla.--(BUSINESS WIRE)--Kari Miller, Pilgrim’s Regulatory Compliance & Product Management Leader, will speak at the 2017 Generis American Medical Device Summit.

 

RefleXion Medical Chooses MedCrypt to Provide Medical Device Security for First-to-Market Radiotherapy TechnologyOpen in a New Window

ENCINITAS, Calif.--(BUSINESS WIRE)--#IoT--MedCrypt chosen to secure and protect RefleXion Medical's first-to-market biology-guided radiotherapy system for cancer treatment

 

Ensysce Biosciences Inc. to Present at 11th Annual Pain and Migraine Therapeutic Summit in San Diego, CA on September 27, 2017Open in a New Window

SAN DIEGO--(BUSINESS WIRE)--Dr. Lynn Kirkpatrick, Ensysce Biosciences Inc., to present at the 11th Annual Pain & Migraine Therapeutics Summit, San Diego, CA on Sept. 27, 2017.

 

Computing Pioneer Gordon Bell to Share Insights and Inspiration at High Performance Computing ConferenceOpen in a New Window

DENVER--(BUSINESS WIRE)--#ACM--Gordon Bell, a globally recognized pioneer in the supercomputing world, will be speak this November at SC17 - the world's largest HPC conference.

 

Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics SocietyOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA conjugate platform at the 13th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 24 – 27, 2017 in Bordeaux, France. ESC+ GalNAc conjugates utilize advanced design features to further improve

 

Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMAOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT) today announced that the Centers for Medicare & Medicaid Services (CMS) published preliminary 2018 rates for clinical diagnostic laboratory tests. The reimbursement rate for the Afirma Genomic Classifier (code 81545) is expected to increase from $3,220 to $3,600 for calendar year 2018. The preliminary rate is based on the median of private payer payments submitted by Veracyte as part of the market-based payment refo

 

Pulse Biosciences Announces $30 Million Private PlacementOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an accredited investor and experienced life sciences executive, for the purchase of 2,000,000 shares of the Company’s common stock at a price of $15.02 per share, the last reported sale price of the C

 

Ocular Therapeutix™ Appoints Donald Notman as Chief Financial OfficerOpen in a New Window

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Donald Notman as Chief Financial Officer, effective immediately. With over 20 years of financial operations and senior-level investment banking experience, Mr. Notman brings a distinguished track record of success to Ocular Therapeuti

 

China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus InfectionOpen in a New Window

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen.

 

Vium Appoints Wendel Barr as CEO and Strengthens Executive TeamOpen in a New Window

SAN MATEO, Calif.--(BUSINESS WIRE)--#DigitalVivarium--Vium appoints Wendel Barr as CEO; strengthens and expands leadership team to prepare for next phase of scientific innovation and commercial growth.

 

Cohen Veterans Network Partners with Artificial Intelligence Company Raiven Healthcare to Serve Veterans and their FamiliesOpen in a New Window

NASHVILLE, Tenn. & STAMFORD, Conn.--(BUSINESS WIRE)--AI innovator Raiven Healthcare is tapped to help the Cohen Veterans Network meet mental health needs of post-9/11 veterans and their families.

 

Sema4 Partners with PWNHealth to Enable Genetic Testing for Consumers NationwideOpen in a New Window

STAMFORD, Conn. & SAN DIEGO--(BUSINESS WIRE)--PWNHealth will provide physician oversight for Sema4’s product CarrierCheck™, which screens for 67 inherited conditions and consumers can buy online.

 

Co-Diagnostics, Inc. to Present at Robins Equity Research Roundup 2017Open in a New Window

SALT LAKE CITY--(BUSINESS WIRE)--Co-Diagnostics, Inc. (NASDAQ: CODX) announced today that it will be presenting at the Third Annual Robins Equity Research Roundup on September 26th.

 

Healthcare Artificial Intelligence Software, Hardware, and Services Market to Reach $19.3 Billion Worldwide by 2025, According to TracticaOpen in a New Window

BOULDER, Colo.--(BUSINESS WIRE)--#ai--AI applications for healthcare are focused on making diagnosis, monitoring, and treatment of patients more efficient, accurate, and widely available.

 

Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review StatusOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--The FDA has accepted for filing with Priority Review the Aradigm NDA for Linhaliq for the treatment of non-CF bronchiectasis

 

Presage Biosciences Awarded Debut Grant from the Mark Foundation for Cancer Research to Support Immuno-Oncology Applications of CIVO™, an Intratumoral Microdosing PlatformOpen in a New Window

SEATTLE--(BUSINESS WIRE)--Presage and The Mark Foundation for Cancer Research announce first-ever grant for intratumoral microdosing platform in immuno-oncology combinations.

 

Coalition for 21st Century Medicine Commends CMS for Issuing 2018 Preliminary Private Payor Rate-Based Payment Amounts for Clinical Diagnostic Laboratory Tests as Part of PAMA ImplementationOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--On September 22, the Centers for Medicare & Medicaid Services (CMS) released its 2018 preliminary private payor rate-based payment amounts for clinical diagnostic laboratory tests. The preliminary rates are based on private payor rates reported by laboratories and are part of the market-based payment reforms enacted in Section 216 of the Protecting Access to Medicare Act of 2014 (PAMA). CMS plans to finalize the market-based Clinical Laboratory Fee Schedule (CLF

 

Tango Therapeutics Appoints Barbara Weber, M.D., as Chief Executive OfficerOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics today announced that Barbara Weber, M.D., has been named the company’s full-time Chief Executive Officer. 

 

SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical ProgramsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs

 

BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime ShareholdersOpen in a New Window

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, announced today that its Board of Directors has approved a distribution of some or all of the shares of AgeX Therapeutics, Inc. owned by BioTime to BioTime’s shareholders. The Board also authorized management to work with investment banks and other financial institutions to finalize and implement the str

 

TherapeuticsMD Announces Move to Nasdaq Global Select MarketOpen in a New Window

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD moves to the Nasdaq on October 9

 

Aerie Pharmaceuticals Announces Appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science LiaisonsOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons, reporting to Welyn Bui, PharmD, Aerie’s National Director of Medical Affairs. Dr. Elliott will be responsible for lea

 

Saranas Appoints Philippe Généreux, MD, as Chief Medical OfficerOpen in a New Window

HOUSTON--(BUSINESS WIRE)--Saranas names new Chief Medical Officer and Scientific Advisory Board

 

La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018Open in a New Window

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued favorable Scientific Advice regarding the EU regulatory pathway for LJPC-501 (angiotensin II) for the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy. Based on this Advice, La Jolla inten

 

USA In-Vitro Diagnostics Market 2017-2022 - Growth, Trends & Forecasts - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "USA In-Vitro Diagnostics Market - Growth, Trends & Forecast 2017 - 2022" report has been added to Research and Markets' offering. The USA's market for In-Vitro Diagnostics is currently estimated to be worth USD 11.54 billion in the year 2014 and is expected to reach USD 15.14 billion by the end of 2020. The CAGR during this period of the forecast is 5.57%. Currently, North America dominates the global market, with the market yet to reach saturation. The USA is

 

NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic CancerOpen in a New Window

AMES, Iowa--(BUSINESS WIRE)--$AZN #clinicaltrial--NewLink Genetics announces collaboration with AstraZeneca to evaluate immuno-oncology based combination therapies in pancreatic cancer.

 

Amsel Medical Corporation Announces Clearance of a 510(k) Pre-Marketing Notification by the US Food and Drug Administration for the Low-Profile Amsel Occluder DeviceOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amsel Medical Corporation today announced clearance of a Pre-Marketing Notification (510(k)) by the US Food and Drug Administration (FDA) for its Low-Profile Amsel Occluder Device1. The Pre-Market Notification is the second 510(k) clearance2 received by the company for its family of Amsel Occluder Devices. The Amsel Occluder Device is intended for use in open general surgery procedures on tubular structures or vessels wherever a metal ligating clip is indicate

 

LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare BeneficiariesOpen in a New Window

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company, today issued the following response to the Sept. 22 publication by the Centers for Medicare and Medicaid Services (CMS) of proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule (CLFS) pursuant to the Protecting Access to Medicare Act (PAMA). “The new PAMA rates published by CMS do not reflect the intent of Congress when it directed CMS to implemen

 

22nd Century Now Free of Restrictive License Agreement with British American TobaccoOpen in a New Window

CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Now Free of Restrictive License Agreement with British American Tobacco; $25 Million Royalty Cap is Null and Void

 

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this FallOpen in a New Window

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines, today announced that the Company will give presentations at several upcoming scientific and partnering conferences in Asia, Europe and the US including: CTRMS 2017 - Cell Transplant and Regenerative Medicine Society Meeting Date: September 26-29, 2017Venue: Halifax, Nova Scotia, Canada 16th Sachs Annual Biotech in Europe Forum Date: September 27-28, 2017Venue: Basel, Switzerland

 

Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal StudyOpen in a New Window

BOSTON--(BUSINESS WIRE)--Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal Study

 

Konica Minolta Accelerates Expansion of Precision Medicine Business Through Acquisition of US-based Pharmaceutical Research Company, InvicroOpen in a New Window

TOKYO & BOSTON--(BUSINESS WIRE)--Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902; ISIN: JP3300600008) and Boston-based Invicro LLC (“Invicro”) today announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development. Invicro is a global Contract Research Organization (CRO) providing imaging services to the pharmaceutical and biotechnology industry from early phase discovery throu

Abbott

BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839 admin@bioflorida.com
Membership Management Software Powered by YourMembership  ::  Legal